A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, c-MET
Location: Lebanon NH, East Brunswick NJ, Rockledge FL, Brampton,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155187
Phase 2, Phase 3, Recruiting
Featured
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, Mullica Hill NJ, Bethlehem PA, Fairfax VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07365241
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: The Bronx NY, Tampa FL, Atlanta GA, St Louis MO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07581002
Phase 2, Phase 3, Recruiting
Featured
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Washington D.C. DC, Pittsburgh PA, Sterling Heights MI,
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase 3, Recruiting
Featured
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
for
Advanced Prostate Cancer, Metastatic Prostate Cancer
Location: Nashville TN, Scottsdale AZ
Sponsor: Genentech, Inc.
Sex: Male
Age: 18+
Code: NCT07567846
Phase 1, Phase 2, Recruiting
Interested in new solid tumors trials?
Get alerts for new trials in your area by subscribing now
Featured
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: New Haven CT, Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07490301
Phase 2, Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, New York NY, Camden NJ,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase 2, Recruiting
Featured
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
for
Multiple Myeloma
Location: New Haven CT, Washington D.C. DC, Winston-Salem NC,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07555938
Phase 3, Recruiting
Featured
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
for
Multiple Myeloma
Location: Tampa FL, Newnan GA, Grand Rapids MI, Chicago IL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07409246
Phase 1, Recruiting
Featured
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Location: Providence RI, Teaneck NJ, Syracuse NY, Fairfax VA,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07024784
Phase 2, Recruiting
Featured
To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
for
Breast Cancer
Location: East Brunswick NJ, Jacksonville FL, Kansas City MO,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07368998
Phase 2, Recruiting
Featured
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
for
Metastatic Castration-Resistant Prostate Cancer
Location: Providence RI, The Bronx NY, Montreal, Myrtle Beach SC,
Sponsor: Hoffmann-La Roche
Sex: Male
Age: 18+
Code: NCT07287150
Phase 2, Recruiting
Featured
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, New Haven CT, Fairfax VA, Ocala FL, Tampa FL,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155174
Phase 2, Recruiting
Featured
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
for
Advanced Squamous Tumors
Location: Montreal, Toronto, Huntersville NC, Grand Rapids MI,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07241039
Phase 1, Recruiting
Featured
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Location: Providence RI, New York NY, Fairfax VA, Durham NC,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06084481
Phase 1, Recruiting
Featured
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
for
Epithelial Ovarian Cancer, Fallopian Tube Cancer,
Location: Providence RI, New Haven CT, Lebanon NH, Bay Shore NY,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT06890338
Phase 2, Recruiting
Featured
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
for
Colorectal Cancer
Location: New Haven CT, Lake Success NY, East Brunswick NJ,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07525206
Phase 3, Recruiting
Featured
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: Valhalla NY, Atlanta GA, Nashville TN, Dallas TX,
Sponsor: AbbVie
Sex: All
Age: 0 - 17
Code: NCT07306832
Phase 1, Recruiting
Featured
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Location: Rimouski, Boston MA, Worcester MA, Hartford CT, Quebec,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06793215
Phase 3, Recruiting
Featured
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive